Skip to main content
SpringerLink
Log in

Metabolic Cardiomyopathy

  • Chapter
  • First Online:
Clinical Cardiogenetics

  • 669 Accesses

Abstract

Metabolic cardiomyopathies represent a large heterogeneous group of diseases caused by inborn errors of metabolism (IEM). So far, more than 1000 distinct disorders of metabolism have been described. Cardiac involvement is present in about 5% of these metabolic defects. While in some diseases, the cardiac involvement is representing the dominant and potentially fatal condition, in the others it may be only part of a complex multisystemic disease manifestation.

Cardiac involvement has been described in various types of metabolic defects including lysosomal storage diseases, different types of glycogenoses and other inborn errors of metabolism such as disorders of amino acid metabolism, organic acid metabolism, and fatty acid metabolism. In broader term of the definition, metabolic cardiomyopathies include also oxidative phosphorylation defects (OXPHOS) usually listed among mitochondrial diseases.

Most IEM are inherited as autosomal recessive traits, however, some highly prevalent diseases with cardiac involvement are X-linked (Anderson Fabry disease, Hunter syndrome—type II mucopolysaccharidosis, Danon disease).

Cardiomyopathies caused by IEM are phenotypically heterogeneous, most of them characterized by cardiac hypertrophy and/or by different degrees of progressive dilatation and systolic dysfunction resulting in dilated cardiomyopathy phenotype. However, several diseases may appear as restrictive cardiomyopathy phenotype. The tableau of the disease may include different electrophysiological changes (short PR, preexcitation pattern, AV conduction abnormalities) and/or valvular involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sweet ME, Mestroni L, Taylor MRG. Genetic infiltrative cardiomyopathies. Heart Fail Clin. 2018;14(2):215–24.

    PubMed  PubMed Central  Google Scholar 

  2. Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol. 2007;24(1):15–25.

    PubMed  PubMed Central  Google Scholar 

  3. Fukao T, Sasai H, Aoyama Y, Otsuka H, Ago Y, Matsumoto H, Abdelkreem E. Recent advances in understanding beta-ketothiolase (mitochondrial acetoacetyl-CoA thiolase, T2) deficiency. J Hum Genet. 2019;64(2):99–111.

    CAS  PubMed  Google Scholar 

  4. Arora N, Stumper O, Wright J, Kelly DA, McKiernan PJ. Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis. 2006;29(1):54–7.

    CAS  PubMed  Google Scholar 

  5. Lorenzo V, Torres A, Salido E. Primary hyperoxaluria. Nefrologia. 2014;34(3):398–412.

    PubMed  Google Scholar 

  6. Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med. 2018;6(24):473.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Nair V, Belanger EC, Veinot JP. Lysosomal storage disorders affecting the heart: a review. Cardiovasc Pathol. 2019;39:12–24.

    Google Scholar 

  8. Linhart A, Cecchi F. Common presentation of rare diseases: left ventricular hypertrophy and diastolic dysfunction. Int J Cardiol. 2018;257:344–50.

    PubMed  Google Scholar 

  9. Arbustini E, Di Toro A, Giuliani L, Favalli V, Narula N, Grasso M. Cardiac phenotypes in hereditary muscle disorders: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(20):2485–506.

    PubMed  Google Scholar 

  10. Akhtar M, Elliott P. The genetics of hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018;2018(3):36.

    PubMed  PubMed Central  Google Scholar 

  11. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647–55.

    PubMed  Google Scholar 

  12. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet. 2018;55(4):261–8.

    Google Scholar 

  13. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867–76.

    CAS  PubMed  Google Scholar 

  14. Thevenon J, Laurent G, Ader F, Laforêt P, Klug D, Duva Pentiah A, Gouya L, Maurage CA, Kacet S, Eicher JC, Albuisson J, Desnos M, Bieth E, Duboc D, Martin L, Réant P, Picard F, Bonithon-Kopp C, Gautier E, Binquet C, Thauvin-Robinet C, Faivre L, Bouvagnet P, Charron P, Richard P. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations. Europace. 2017;19(4):651–9.

    PubMed  Google Scholar 

  15. Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. J Am Coll Cardiol. 2016;68(25):2871–86.

    PubMed  PubMed Central  Google Scholar 

  17. Vasilescu C, Ojala TH, Brilhante V, Ojanen S, Hinterding HM, Palin E, Alastalo TP, Koskenvuo J, Hiippala A, Jokinen E, Jahnukainen T, Lohi J, Pihkala J, Tyni TA, Carroll CJ, Suomalainen A. Genetic basis of severe childhood-onset cardiomyopathies. J Am Coll Cardiol. 2018;72(19):2324–38.

    CAS  PubMed  Google Scholar 

  18. Lipshultz SE, Cochran TR, Briston DA, Brown SR, Sambatakos PJ, Miller TL, Carrillo AA, Corcia L, Sanchez JE, Diamond MB, Freundlich M, Harake D, Gayle T, Harmon WG, Rusconi PG, Sandhu SK, Wilkinson JD. Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol. 2013;9(6):817–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, Zeman J, Ledvinová J, Poupetová H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139(6):1101–8.

    CAS  PubMed  Google Scholar 

  20. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, Olson JB, Milliner DS. International registry for primary hyperoxaluria. Am J Nephrol. 2005;25(3):290–6.

    PubMed  Google Scholar 

  21. Salido E, Pey AL, Rodriguez R, Lorenzo V. Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim Biophys Acta. 2012;1822(9):1453–64.

    CAS  PubMed  Google Scholar 

  22. Wilcken B, Wiley V, Sim KG, Carpenter K. Carnitine transporter defect diagnosed by newborn screening with electrospray tandem mass spectrometry. J Pediatr. 2001;138(4):581–4.

    CAS  PubMed  Google Scholar 

  23. Fu L, Huang M, Chen S. Primary carnitine deficiency and cardiomyopathy.Korean. Circ J. 2013;43(12):785–92.

    Google Scholar 

  24. Frigeni M, Balakrishnan B, Yin X, Calderon FRO, Mao R, Pasquali M, Longo N. Functional and molecular studies in primary carnitine deficiency. Hum Mutat. 2017;38(12):1684–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Guertl B, Noehammer C, Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol. 2000;81(6):349–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Vishwanath VA. Fatty acid beta-oxidation disorders: a brief review. Ann Neurosci. 2016;23(1):51–5.

    PubMed  PubMed Central  Google Scholar 

  27. Kang E, Kim YM, Kang M, Heo SH, Kim GH, Choi IH, Choi JH, Yoo HW, Lee BH. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening. BMC Pediatr. 2018;18(1):103.

    Google Scholar 

  28. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236–242.

    Google Scholar 

  29. Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44–54.

    CAS  PubMed  Google Scholar 

  30. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93(4):528–35.

    PubMed  PubMed Central  Google Scholar 

  31. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM, European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28(10):1228–35.

    PubMed  Google Scholar 

  32. Militaru S, Ginghina C, Popescu BA, Saftoiu A, Linhart A, Jurcut R. Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets. Eur Heart J Cardiovasc Imaging. 2018;19(12):1313–22.

    PubMed  Google Scholar 

  33. Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, Laney DA, Linhart A, Maródi L, Nicholls K, Ortiz A, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genomic Med. 2018. https://doi.org/10.1002/mgg3.389.

  34. Nowak A, Mechtler T, Kasper DC, Desnick RJ. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease. Mol Genet Metab. 2017;121(4):320–4.

    CAS  PubMed  Google Scholar 

  35. Kramer J, Weidemann F. Biomarkers for diagnosing and staging of Fabry disease. Curr Med Chem. 2018;25(13):1530–7.

    CAS  PubMed  Google Scholar 

  36. Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J, Weidemann F, West ML, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B, van der Wal AC, van den Bergh Weerman MA, Hollak CE. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177(2):400–8.

    CAS  PubMed  Google Scholar 

  37. Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454.

    PubMed  PubMed Central  Google Scholar 

  38. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189–203.

    CAS  PubMed  Google Scholar 

  39. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–27.

    CAS  PubMed  Google Scholar 

  40. Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288–96.

    Google Scholar 

  41. Welford RWD, Mühlemann A, Garzotti M, Rickert V, Groenen PMA, Morand O, Üçeyler N, Probst MR. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet. 2018;27(19):3392–403.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Guérard N, Morand O, Dingemanse J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis. 2017;12(1):9.

    PubMed  PubMed Central  Google Scholar 

  43. Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016; 375(6):545–55.

    Google Scholar 

  44. Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v4–12.

    Google Scholar 

  46. Braunlin E, Wang R. Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs. Heart. 2016;102(16):1257–62.

    PubMed  Google Scholar 

  47. Soliman OI, Timmermans RG, Nemes A, Vletter WB, Wilson JH, ten Cate FJ, Geleijnse ML. Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I. J Inherit Metab Dis. 2007;30(5):750–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Wraith JE, Jones S. Mucopolysaccharidosis type I. Pediatr Endocrinol Rev. 2014;12(Suppl 1):102–6.

    PubMed  Google Scholar 

  49. Hendriksz CJ, Berger KI, Giugliani R, Harmatz P, Kampmann C, Mackenzie WG, Raiman J, Villarreal MS, Savarirayan R. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167A(1):11–25.

    PubMed  Google Scholar 

  50. Lin HY, Chuang CK, Chen MR, Lin SM, Hung CL, Chang CY, Chiu PC, Tsai WH, Niu DM, Tsai FJ, Lin SJ, Hwu WL, Lin JL, Lin SP. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab. 2016;117(4):431–7.

    CAS  PubMed  Google Scholar 

  51. Kampmann C, Lampe C, Whybra-Trümpler C, Wiethoff CM, Mengel E, Arash L, Beck M, Miebach E. Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy. J Inherit Metab Dis. 2014;37(2):269–76.

    CAS  PubMed  Google Scholar 

  52. Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, Guffon N, Ketteridge D, Sá Miranda CM, Scarpa M, Schwartz IV, Leão Teles E, Wraith JE, Barrios P, Dias da Silva E, Kurio G, Richardson M, Gildengorin G, Hopwood JJ, Imperiale M, Schatz A, Decker C, Harmatz P, MPS VI Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. J Inherit Metab Dis. 2013;36(2):385–94.

    CAS  PubMed  Google Scholar 

  53. Montaño AM, Lock-Hock N, Steiner RD, Graham BH, Szlago M, Greenstein R, Pineda M, Gonzalez-Meneses A, Çoker M, Bartholomew D, Sands MS, Wang R, Giugliani R, Macaya A, Pastores G, Ketko AK, Ezgü F, Tanaka A, Arash L, Beck M, Falk RE, Bhattacharya K, Franco J, White KK, Mitchell GA, Cimbalistiene L, Holtz M, Sly WS. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016;53(6):403–18.

    PubMed  PubMed Central  Google Scholar 

  54. McCafferty EH, Scott LJ. Vestronidase alfa: a review in mucopolysaccharidosis VII. BioDrugs. 2019;33(2):233–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Hack HA, Walker R, Gardiner P. Anaesthetic implications of the changing management of patients with mucopolysaccharidosis. Anaesth Intensive Care. 2016;44(6):660–8.

    CAS  PubMed  Google Scholar 

  56. Walker R, Belani KG, Braunlin EA, Bruce IA, Hack H, Harmatz PR, Jones S, Rowe R, Solanki GA, Valdemarsson B. Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36(2):211–9.

    CAS  PubMed  Google Scholar 

  57. Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, Ponder KP, Roberts WC, Rosenfeld HM, Giugliani R. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34(6):1183–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Braunlin E, Orchard PJ, Whitley CB, Schroeder L, Reed RC, Manivel JC. Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review. Cardiovasc Pathol. 2014;23(3):145–51.

    CAS  PubMed  Google Scholar 

  59. Boffi L, Russo P, Limongelli G. Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists. Ital J Pediatr. 2018;44(Suppl 2):122.

    PubMed  PubMed Central  Google Scholar 

  60. Muenzer J, Wraith JE. Clarke LA; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123(1):19–29.

    PubMed  Google Scholar 

  61. Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK, Tolar J, Allewelt H, Jones SA, Parini R, Renard M, Bordon V, Wulffraat NM, de Koning TJ, Shapiro EG, Kurtzberg J, Boelens JJ. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125(13):2164–72.

    CAS  PubMed  Google Scholar 

  62. Laraway S, Mercer J, Jameson E, Ashworth J, Hensman P, Jones SA. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I. J Pediatr. 2016;178:219–26.e1.

    Google Scholar 

  63. Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120

    Google Scholar 

  64. Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111(2):63–72.

    CAS  PubMed  Google Scholar 

  65. Hicks J, Wartchow E, Mierau G. Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol. 2011;35(5):183–96.

    PubMed  Google Scholar 

  66. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O’Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–88.

    PubMed  PubMed Central  Google Scholar 

  67. Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, Musumeci O, Parenti G, Ravaglia S, Seidita F, Toscano A, Vianello A. Diagnosis of glycogenosis type II. Neurology. 2008;71(23 Suppl 2):S4–11.

    CAS  PubMed  Google Scholar 

  68. Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN, Kishnani PS. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120(3):163–72.

    CAS  PubMed  Google Scholar 

  69. Boentert M, Florian A, Dräger B, Young P, Yilmaz A. Pattern and prognostic value of cardiac involvement in patients with late-onset Pompe disease: a comprehensive cardiovascular magnetic resonance approach. J Cardiovasc Magn Reson. 2016;18(1):91.

    PubMed  PubMed Central  Google Scholar 

  70. Fayssoil A. Cardiomyopathy in Pompe’s disease. Eur J Intern Med. 2008;19(1):57–9.

    CAS  PubMed  Google Scholar 

  71. Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621–30.

    Google Scholar 

  72. Joanne M, Skye N, Tracy M. The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review. J Inherit Metab Dis. 2019;42(1):57–65.

    PubMed  Google Scholar 

  73. Vita G, Vita GL, Musumeci O, Rodolico C, Messina S. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurol Sci. 2019;40(4):671–81.

    PubMed  Google Scholar 

  74. D’souza RS, Levandowski C, Slavov D, Graw SL, Allen LA, Adler E, Mestroni L, Taylor MR. Danon disease: clinical features, evaluation, and management. Circ Heart Fail. 2014;7(5):843–9.

    PubMed  PubMed Central  Google Scholar 

  75. Nascimbeni AC, Fanin M, Angelini C, Sandri M. Autophagy dysregulation in Danon disease. Cell Death Dis. 2017;8(1):e2565.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Konrad T, Sonnenschein S, Schmidt FP, Mollnau H, Bock K, Ocete BQ, Münzel T, Theis C, Rostock T. Cardiac arrhythmias in patients with Danon disease. Europace. 2017;19(7):1204–10.

    PubMed  Google Scholar 

  77. Sternick EB, Oliva A, Magalhães LP, Gerken LM, Hong K, Santana O, Brugada P, Brugada J, Brugada R. Familial pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol. 2006;17(7):724–32.

    PubMed  Google Scholar 

  78. Arad M. Cardiac Danon disease: insights and challenges. Int J Cardiol. 2017;245:211–2.

    PubMed  Google Scholar 

  79. Rowland TJ, Sweet ME, Mestroni L, Taylor MR. Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci. 2016;129(11):2135–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Brambatti M, Caspi O, Maolo A, Koshi E, Greenberg B, Taylor MRG, Adler ED. Danon disease: gender differences in presentation and outcomes. Int J Cardiol. 2019;286:92–8.

    PubMed  Google Scholar 

  81. Konrad T, Sonnenschein S, Schmidt FP, Mollnau H, Bock K, Ocete BQ, Münzel T, Theis C, Rostock T. Cardiac arrhythmias in patients with Danon disease. Europace. 2017;19(7):1204–10.

    Google Scholar 

  82. Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011;13:563–8.

    PubMed  Google Scholar 

  83. Stokes MB, Taylor AJ, McLean CA, D’Arcy CE, Mariani JA. Severe left ventricular hypertrophy and marked cardiac fibrosis in Danon disease. Int J Cardiol. 2016;221:14–6.

    PubMed  Google Scholar 

  84. Ng KM, Mok PY, Butler AW, Ho JC, Choi SW, Lee YK, Lai WH, Au KW, Lau YM, Wong LY, Esteban MA, Siu CW, Sham PC, Colman A, Tse HF. Amelioration of X-linked related autophagy failure in Danon disease with DNA methylation inhibitor. Circulation. 2016;134(18):1373–89.

    CAS  PubMed  Google Scholar 

  85. Finsterer J, Stöllberger C, Maeztu C. Sudden cardiac death in neuromuscular disorders. Int J Cardiol. 2016;203:508–15.

    PubMed  Google Scholar 

  86. Zaha VYL. Amp-activated protein kinase regulation and biological actions in the heart. Circ Res. 2012;111:800–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Hedberg-Oldfors C, Oldfors A. Polyglucosan storage myopathies. Mol Aspects Med. 2015;46:85–100.

    CAS  PubMed  Google Scholar 

  88. Murphy RT, Mogensen J, McGarry K, Bahl A, Evans A, Osman E, Syrris P, Gorman G, Farrell M, Holton JL, Hanna MG, Hughes S, Elliott PM, Macrae CA, McKenna WJ. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol. 2005;45(6):922–30.

    CAS  PubMed  Google Scholar 

  89. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344(24):1823–31.

    CAS  PubMed  Google Scholar 

  90. Porto AG, Brun F, Severini GM, Losurdo P, Fabris E, Taylor MRG, Mestroni L, Sinagra G. Clinical spectrum of PRKAG2 syndrome. Circ Arrhythm Electrophysiol. 2016;9(1):e003121.

    PubMed  Google Scholar 

  91. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352(4):362–72.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic

    Aleš Linhart

Authors
  1. Aleš Linhart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aleš Linhart .

Editor information

Editors and Affiliations

  1. Consultant Cardiologist at the OLVG Hospital, Amsterdam, The Netherlands

    Hubert F. Baars

  2. Utrecht University, Utrecht, The Netherlands

    Pieter A. F. M. Doevendans

  3. Amsterdam University Medical Center, Amsterdam, The Netherlands

    Arjan C. Houweling

  4. University Medical Center Utrecht, Utrecht, The Netherlands

    J. Peter van Tintelen

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Linhart, A. (2020). Metabolic Cardiomyopathy. In: Baars, H.F., Doevendans, P.A.F.M., Houweling, A.C., van Tintelen, J.P. (eds) Clinical Cardiogenetics. Springer, Cham. https://doi.org/10.1007/978-3-030-45457-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45457-9_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45456-2

  • Online ISBN: 978-3-030-45457-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation